Streetbeat News

Products Services

CMC

Commercial Metals Company (CMC) anticipates a compression in margins for steel products in Q2, but expects recent price announcements to lead to an inflection point and improved margins subsequently.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:50 am

MDT

Medtronic has received CE Mark approval in Europe for its MiniMed 780G system, which includes the Simplera Sync, a disposable continuous glucose monitor that eliminates the need for fingersticks or overtape. This regulatory milestone could enhance Medtronic's product offering in the diabetes care market in Europe.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:47 am

BEAM

Beam Therapeutics has announced progress in its hematology and genetic disease portfolios, with sufficient cash to support its operations into 2027. This update indicates a strong financial position and ongoing advancements in its medical research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:39 am

REGN

Regeneron Pharmaceuticals reported preliminary Q4 2023 U.S. net product sales for EyleaHD (Aflibercept) Injection 8mg at approximately $123M, and for Eylea (Aflibercept) Injection at approximately $1.34B, according to an 8K filing.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:38 am

NUVL

Nuvalent has unveiled its 'OnTarget 2026' operating plan, aiming to have its first potential product approved by 2026. The company expects its operating runway to extend into 2027, indicating a strategic roadmap for development and financial stability.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:35 am

CCK

COP

META

MSFT

RMBS

Wall Street's most accurate analysts have made recent stock picks with significant upside potential. Scott Devitt from Wedbush maintains an Outperform rating on Meta Platforms (META) with a price target increase to $420, seeing a 19% upside. John Freeman of Raymond James keeps a Strong Buy on ConocoPhillips (COP) with a reduced target of $140, indicating a 21% upside. John Roberts from Mizuho continues a Buy rating on Crown Holdings (CCK) with a target raised to $105, a 14% upside. Kevin Cassidy of Rosenblatt reiterates a Buy on Rambus (RMBS) with an $85 target, suggesting a 25% surge. Daniel Ives of Wedbush maintains an Outperform on Microsoft (MSFT) with a target upped to $450, a 20% upside. Meta Platforms is launching a fact-checking program, ConocoPhillips is advancing the Willow project, Crown Holdings posted in-line Q3 earnings, Rambus announced a new DDR5 RCD, and Microsoft introduced an AI-driven app for Android.

Portfolio Pulse from Avi Kapoor

January 08, 2024 | 11:33 am

GELYY

Geely Automobile Holding's electric car subsidiary, Zeekr, aims to double its car deliveries to 230,000 vehicles in 2024. Zeekr experienced a 65% increase in sales in 2023, delivering 118,685 cars but fell short of its 140,000 target. The company is expanding in Europe, the Middle East, and Asia, and postponed its U.S. IPO due to valuation issues and market instability. Geely's stock (GELYY) closed slightly higher at $21.38.

Portfolio Pulse from Shivani Kumaresan

January 08, 2024 | 11:29 am

VRSK

Verisk (NASDAQ:VRSK), a data analytics and technology provider, has received approval from the California Department of Insurance for its ISO wildfire mitigation filings. These filings allow insurers to apply specific wildfire mitigation discounts to their rating plans, complying with a CDI regulation. Verisk's proactive engagement with CDI and its position as an industry leader is highlighted by being among the first to have its filings approved.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:18 am

KBR

KBR, Inc. has been selected to provide its K-GreeN technology for Lotte Chemical's H2biscus green ammonia project in Malaysia. The project, involving a consortium including Lotte Chemical, KNOC, and Samsung Engineering, will produce 800 KTA of green ammonia using hydropower. Financial terms of the contract were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 11:10 am

AMGN

BMY

MRNA

SRPT

VRTX

XBI

The 42nd annual JPMorgan Healthcare Conference begins in San Francisco, with expectations of significant industry discussions, potential deal announcements, and company presentations. Past conferences have influenced M&A activity and stock volatility. Bristol-Myers Squibb, Vertex Pharmaceuticals, Amgen, Sarepta Therapeutics, and Moderna are among the companies presenting. The SPDR S&P Biotech ETF (XBI) has shown varied performance during past conferences, with individual stocks potentially experiencing volatility based on news from the event.

Portfolio Pulse from Shanthi Rexaline

January 08, 2024 | 11:04 am